{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125523","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.694490+00:00","generated_at":"2026-05-30T01:50:22.810305+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Synlogic posts Q3 net loss of $0.1M, cash $19.4M; evaluating strategic options","bullets":["Net loss of $0.1M ($0.01 per share) vs $12.1M ($2.57 loss per share) in Q3 2023.","Cash and cash equivalents of $19.4M as of Sep 30, 2024; no revenue for Q3.","R&D expenses show $0.7M benefit due to clinical trial refund and accrual reversal.","Restructuring charges of $0.3M related to workforce reduction from Synpheny-3 discontinuation.","Retained Lucid Capital Markets to explore strategic alternatives including M&A or business combination."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125523","json":"https://secwatch.observer/filing/0000950170-24-125523.json","markdown":"https://secwatch.observer/filing/0000950170-24-125523.md","text":"https://secwatch.observer/filing/0000950170-24-125523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/0000950170-24-125523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/sybx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:50:22.810305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}